Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Qian Xing

Showing results (191-200 of 193) with videos related to

Pageof 20
Sort By:
You have reached the last page of results.This site can display upto 193 results.
Endocrine Journal|December 8, 2010
The relationship between serum thyrotropin and components of metabolic syndromeYaxin Lai, Jiani Wang, Fengwei Jiang, et al.
International Journal of Clinical and Experimental Medicine|November 10, 2015
Sphingosine kinase 1/sphingosine 1-phosphate signalling pathway as a potential therapeutic target of pulmonary hypertensionXi-Qian Xing, Yan-Li Li, Yu-Xuan Zhang, et al.
The Lancet. Rheumatology|January 17, 2024
IBI303, a biosimilar to adalimumab, for the treatment of patients with ankylosing spondylitis in China: a randomised, double-blind, phase 3 equivalence trialHuji Xu, Zhijun Li, Jian Wu, et al.
Pageof 20

Showing results (191-200 of 193) with videos related to

Sort By:
Pageof 20
You have reached the last page of results.This site can display upto 193 results.
Endocrine Journal|December 8, 2010
The relationship between serum thyrotropin and components of metabolic syndromeYaxin Lai, Jiani Wang, Fengwei Jiang, et al.
International Journal of Clinical and Experimental Medicine|November 10, 2015
Sphingosine kinase 1/sphingosine 1-phosphate signalling pathway as a potential therapeutic target of pulmonary hypertensionXi-Qian Xing, Yan-Li Li, Yu-Xuan Zhang, et al.
The Lancet. Rheumatology|January 17, 2024
IBI303, a biosimilar to adalimumab, for the treatment of patients with ankylosing spondylitis in China: a randomised, double-blind, phase 3 equivalence trialHuji Xu, Zhijun Li, Jian Wu, et al.
Pageof 20